Press Releases Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
0.3162 ^USD	-6.81%		+12.81%	-77.25%

Apr. 29	Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	CI
Mar. 19	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations	Apr. 29	PR
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)	Mar. 19	PR
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	Jan. 29	AQ
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	Jan. 26	PR
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration	Jan. 23	AQ
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	Jan. 22	PR
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote 'FOR' All Proxy Proposals at the Special Meeting to be held on January 10, 2024	Jan. 03	AQ
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024	Jan. 02	PR
Seelos Therapeutics, Inc. Releases Letter to its Stockholders	Dec. 22	PR
Seelos Therapeutics Announces the Selection of SLS-002 for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder	Nov. 28	AQ
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split	Nov. 27	AQ
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)	Nov. 27	PR
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split	Nov. 24	PR
Seelos: Q3 Earnings Snapshot	Nov. 15	AQ
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's disease at Neuroscience 2023	23-10-30	AQ
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023	23-10-27	PR
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations	23-10-17	PR
Seelos Therapeutics : Material Agreement - Form 8-K	23-10-02	PU
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease	23-09-27	PR
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock	23-09-21	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Press Releases

Filters